Search results
Immunic shareholders elect directors, ratify auditor By Investing.com
Investing.com· 5 days agoImmunic, Inc. (NASDAQ:IMUX), a biopharmaceutical company specializing in the development of...
Kymera shares hold Buy rating on PoC data By Investing.com
Investing.com· 1 day agoOn Monday, H.C. Wainwright maintained its Buy rating on Kymera Therapeutics (NASDAQ:KYMR) with a...
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 1 day agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...
Canaccord maintains Buy rating on Akero stock, cites drug candidate 'Efruxifermin' By Investing.com
Investing.com· 6 days agoOn Wednesday, Canaccord Genuity (TSX:CF) expressed continued optimism for Akero Therapeutics...
GameStop Analyst Lowers Price Target After 'Rambling Presentation By Roaring Kitty': Does Video Game...
Benzinga via Yahoo Finance· 6 days agoShares of video game retailer GameStop Corporation (NYSE:GME) have traded higher in recent weeks on...
TD Cowen starts Alkermes stock coverage with Buy By Investing.com
Investing.com· 1 day agoOn Monday, TD Cowen initiated coverage on shares of Alkermes (NASDAQ:ALKS), assigning a Buy rating...
Lixte Biotechnology inks deal for cancer drug trial By Investing.com
Investing.com· 4 days agoLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) has entered into a significant agreement with the...
Tevogen secures $50 million to boost R&D and IP assets By Investing.com
Investing.com· 7 days agoInc. (NASDAQ:TVGN), a biotech firm specializing in immunotherapy, announced a definitive agreement...
Piper Sandler keeps 'Overweight' on Allogene stock, highlights CAR-T potential By Investing.com
Investing.com· 1 day agoOn Monday, Piper Sandler reaffirmed its Overweight rating on Allogene Therapeutics (NASDAQ:ALLO)...
Oppenheimer cuts Spruce Biosciences shares target, cites updated revenue forecasts By Investing.com
Investing.com· 5 days agoOn Thursday, Oppenheimer adjusted its price target for Spruce Biosciences, Inc. (NASDAQ:SPRB)...